870296 | DOPE-RGD Lipid
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-(cysarginylglycylaspartate-maleimidomethyl)cyclohexane-carboxamide] (sodium salt)
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
DOPE-RGD Lipid
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-(cysarginylglycylaspartate-maleimidomethyl)cyclohexane-carboxamide] (sodium salt)
DOPE is a type of lipid, specifically a phospholipid, that is commonly used in the formulation of liposomes and other lipid-based nanoparticles. Liposomes are spherical vesicles with a lipid bilayer structure that can encapsulate various substances, including drugs or molecules of interest. DOPE is often chosen as a component due to its ability to help stabilize and enhance the structural properties of liposomes.
Alternatively, RGD stands for arginine-glycine-aspartic acid, a short peptide sequence with a specific affinity for binding to integrin receptors found on the surfaces of cells. Integrins are a family of cell adhesion receptors that play a crucial role in cell signaling, attachment, and migration. The RGD sequence has been widely studied and used to enhance the targeting of therapeutic agents to specific cells or tissues, such as cancer cells, by utilizing the integrin receptor interaction.
Research shows RGD peptide-based lipids can be used for targeted mRNA delivery and targeted drug delivery. RGD-containing peptides are preferable to other delivery methods due to their advantages, including improved specificity, enhanced cellular uptake, reduced immunogenicity, versatile design, and potential for combination therapies (such as gene therapy).
Lipids formulated with DOPE, cholesterol, and lipid polyethylene glycol have been used to create lipid nanoparticles that helped increase gene editing efficiency.
Lipids containing RGD peptides offer a hopeful strategy for precise mRNA delivery and gene editing. The incorporation of targeted ligands like RGD peptides holds promise in enhancing the accuracy and effectiveness of gene therapies, paving the way for novel treatments targeting diverse genetic disorders.
Avanti Research offers this lipopeptide in high-quality powder form in 1 mg packaging.
C68H116N9Na2O18PS
C 56.07%, H 8.03%, N 8.65%, Na 3.16%, O 19.77%, P 2.13%, S 2.20%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by Bioz- Certificate of Analysis (Lot No. 870296P-1MG-A-010 and 6597PGA010)
- Certificate of Analysis (Lot No. 870296P-1MG-B-010 and 6597PGB010)
- Certificate of Analysis (Lot No. 870296P-1MG-C-010 and 6597PGC010)
- Certificate of Analysis (Lot No. 870296P-1MG-D-010 and 6597PGD010)
- Certificate of Analysis (Lot No. 870296P-1MG-F-010 and 6597PGF010)
- Certificate of Analysis (Lot No. 870296P-1MG-E-010 and 6597PGE010)
- Certificate of Analysis (Lot No. 870296P-1MG-G-010 and 6597PGG010)
- Certificate of Analysis (Lot No. 870296P-1MG-H-010 and 6597PGH010)
